NCT06825754

Brief Summary

By measuring the expression levels of MicroRNA-21-5p (miR-21-5p) and LncRNAgadd7 in the peripheral blood of ARDS patients, the study aims to explore the correlation between these levels and the severity and prognosis of ARDS.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
110

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2023

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2023

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2025

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

February 7, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

February 13, 2025

Completed
Last Updated

February 13, 2025

Status Verified

February 1, 2025

Enrollment Period

1.1 years

First QC Date

February 7, 2025

Last Update Submit

February 7, 2025

Conditions

Acute Respiratory Distress Syndrome

Outcome Measures

Primary Outcomes (2)

  • The expression levels of MicroRNA-21-5p (miR-21-5p)

    28 days

  • the expression levels of LncRNAgadd7

    28 days

Study Arms (2)

Survival Group

Death Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with ARDS ( Acute Respiratory Distress Syndrome)

You may qualify if:

  • Age ≥ 18 years;
  • Meets the Berlin Criteria for ARDS;
  • Diagnosed with ARDS within 48 hours;
  • Signed informed consent.

You may not qualify if:

  • Immunosuppressed patients: including those on immunosuppressive drugs, history of stem cell transplantation, etc.;
  • Patients with malignant tumors;
  • Pregnant women;
  • Patients discharged from the ICU within 48 hours;
  • History of chronic lung diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Affiliated Hospital of Zunyi Medical University

Zunyi, Guizhou, 563100, China

Location

MeSH Terms

Conditions

Respiratory Distress Syndrome

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesRespiration Disorders

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Researcher

Study Record Dates

First Submitted

February 7, 2025

First Posted

February 13, 2025

Study Start

November 1, 2023

Primary Completion

November 30, 2024

Study Completion

January 10, 2025

Last Updated

February 13, 2025

Record last verified: 2025-02

Locations

CN(1)